Stockreport

BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM

BridgeBio Pharma, Inc.  (BBIO) 
Last bridgebio pharma, inc. earnings: 3/2 08:29 am Check Earnings Report
PDF - BridgeBio grants Bayer exclusive license to commercialize acoramidis as a treatment for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in Europe - Bridg [Read more]